| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/EJHF.218 |
| P698 | PubMed publication ID | 25678098 |
| P50 | author | Faiez Zannad | Q19631268 |
| Piotr Ponikowski | Q22114836 | ||
| Stefan D. Anker | Q30310195 | ||
| Henry Krum | Q82083581 | ||
| Adriaan A Voors | Q91537232 | ||
| Christina Nowack | Q114291637 | ||
| Alexander Pieper | Q114291639 | ||
| Nina Kimmeskamp-Kirschbaum | Q114291640 | ||
| Lars Køber | Q33310611 | ||
| Aldo P. Maggioni | Q40310748 | ||
| Mihai Gheorghiade | Q60059386 | ||
| Bertram Pitt | Q63107334 | ||
| Gerasimos Filippatos | Q63107352 | ||
| P2093 | author name string | Michael Böhm | |
| So-Young Kim | |||
| P2860 | cites work | 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines | Q26864648 |
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients | Q81434357 | ||
| Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial) | Q81955371 | ||
| Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury | Q87428114 | ||
| ??? | Q22242895 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
| Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life | Q35137197 | ||
| Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial | Q37066197 | ||
| Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial | Q37094366 | ||
| 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Associ | Q37858859 | ||
| Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics | Q37902778 | ||
| Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial | Q38454911 | ||
| Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. | Q39243083 | ||
| N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. | Q40479579 | ||
| PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy | Q42672479 | ||
| Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases | Q42716993 | ||
| Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure | Q42795421 | ||
| Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease | Q42830307 | ||
| Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction | Q43124593 | ||
| Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress | Q43240308 | ||
| Use of aldosterone antagonists in heart failure | Q43258043 | ||
| Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure | Q43573505 | ||
| Hospitalizations for heart failure in the United States--a sign of hope | Q43599944 | ||
| Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors | Q44188982 | ||
| Eplerenone in patients with systolic heart failure and mild symptoms | Q44272913 | ||
| Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study | Q44485270 | ||
| Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes | Q44657274 | ||
| Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial | Q45069603 | ||
| Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu | Q46034385 | ||
| EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). | Q46275793 | ||
| EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). | Q46414626 | ||
| Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure | Q46466518 | ||
| Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony | Q48273698 | ||
| Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure | Q48335466 | ||
| Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker | Q48358493 | ||
| Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function | Q57396191 | ||
| Acute heart failure in the emergency department: Short and long-term outcomes of elderly patients with heart failure | Q57483731 | ||
| Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee | Q59637921 | ||
| Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients | Q60619537 | ||
| P433 | issue | 2 | |
| P921 | main subject | heart failure | Q181754 |
| chronic heart failure | Q11829287 | ||
| P304 | page(s) | 224-232 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseas | |
| P478 | volume | 17 |
| Q28077170 | A Review of the Key Clinical Trials of 2015: Results and Implications |
| Q37098407 | A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease |
| Q28067064 | Cardio-renal syndrome |
| Q38374127 | Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial |
| Q38780801 | From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure |
| Q38754215 | Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook |
| Q50068164 | Impact of Adrenal Steroids on Regulation of Adipose Tissue. |
| Q46005004 | Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. |
| Q42509316 | Interaction of the Mineralocorticoid Receptor With RACK1 and Its Role in Aldosterone Signaling |
| Q38815451 | Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications |
| Q88711774 | Neurohormonal Blockade in Heart Failure |
| Q38845433 | New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease |
| Q37347190 | New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option? |
| Q38594785 | New medical therapies for heart failure |
| Q42696155 | Newer drugs for heart failure: hype or hope? |
| Q38658657 | Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. |
| Q38806574 | Novel insight into the dangerous connection between diabetes and heart failure |
| Q51293660 | Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. |
| Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q50048824 | Publishing in a heart failure journal-where lies the scientific interest? |
| Q38927295 | Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure |
| Q38496703 | Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em |
| Q39195160 | Redefining the role of biomarkers in heart failure trials: expert consensus document |
| Q38597498 | Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism |
| Q26747017 | Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension |
| Q38746216 | Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis |
| Q38593070 | Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT? |
| Q39199991 | Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside |
| Q36437145 | Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth? |
| Q38705827 | Treatment of Hyperkalemia in Heart Failure |
| Q28077454 | Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease |
| Q37625576 | Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial. |
| Q27008175 | Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic |
Search more.